MHY1485通过抑制自细胞来促进HepG2细胞中的氨酸敏感性
Jingfeng Guo1,2, Yingying Lei3,4, Liwei Liu3,4
1Department of Medical Oncology, He Xian Memorial Affiliated Hospital of Southern Medical University, Guangzhou, China. jfengguo@126.com.
Functional & integrative genomics
|February 2, 2024
概括
作为mTOR激活剂的MHY1485抑制了自并增强了阿德里亚米辛在肝癌细胞中的疗效. 这项研究表明,针对mTOR可以克服肝细胞癌 (HCC) 中的阿德里亚米辛耐药性.
科学领域:
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肝细胞癌 (HCC) 往往会对化疗产生耐药性,例如阿德里亚米辛 (ADM).
- 自是一种细胞过程,在癌症的进展和耐药性方面发挥着复杂的作用.
- 了解自调节对于开发针对HCC的新型治疗策略至关重要.
研究的目的:
- 研究MHY1485的作用和机制,一个mTOR激活剂,在肝细胞癌 (HCC).
- 阐明MHY1485如何影响自在抗阿德里亚米辛 (ADM) 耐药性的背景下.
- 探索MHY1485作为一种潜在的分子向自细胞调节剂,用于HCC治疗.
主要方法:
- 建立了一个抗ADM的HepG2细胞模型 (HepG2/ADM).
- 用MHY1485和ADM治疗的HCC细胞,通过CCK8,克隆形成,流细胞计和EDU染色来评估增殖和亡.
- 通过使用IF染色,qPCR和西部涂抹,分析了关键蛋白质 (Ki-67,mTOR,LC3A,GLUT1,PGI,PFK,END,MTHFD2,caspases) 的表达和酸化.
- 使用单一丹西尔卡达维林染色量化自细胞.
主要成果:
- MHY1485抑制了肝癌细胞的增殖和生长.
- 结合MHY1485和ADM治疗克服了HepG2/ADM细胞中的ADM耐药性,提高了ADM的疗效.
- MHY1485激活了mTOR,抑制了自 (由LC3A变化表明),并增加了肝癌细胞对ADM的敏感性.
结论:
- MHY1485通过激活mTOR和抑制自增强了耐药HCC细胞中的氨酸敏感性.
- 向mTOR代表了一种有前途的治疗策略,用于克服肝癌中阿德里亚米辛耐药性的治疗.
- MHY1485在HCC治疗中显示出作为自调节剂的潜力.
更多相关视频
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
18.7K
11:13Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
1.6K
相关概念视频
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
01:15Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K